Health · Pharma & Biotech · 1 hr ago
FDA approves Sanofi pill for neurological symptoms of Type 3 Gaucher disease
The FDA approved Sanofi’s Infilbray pill for Type 3 Gaucher disease in the United States for adults and children weighing at least 15 kilograms.
It is the first approved treatment for the disease’s neurological symptoms, which can affect thinking and coordination.
Gaucher disease is an inherited disorder, and in Type 3, fatty molecules build up in the central nervous system.
In a trial, one year of treatment significantly improved neurological symptoms.
The drug carries warnings about suicidal thoughts and behavior, eye lens clouding in children, and possible harm to a developing fetus.
The approval gives Sanofi a potential new revenue source as it prepares for the patent expiration of its top-selling drug, Dupixent; Infilbray’s price has not been announced.
The FDA approved Sanofi’s once-daily pill Infilbray as the first treatment for neurologic symptoms of type 3 Gaucher disease.
The approval covers adults and children who weigh at least 15 kilograms.
In a phase 3 trial, a year of treatment was associated with statistically significant improvements in neurological symptoms.
Type 3 Gaucher disease can affect cognitive function and coordination as molecules build up in the central nervous system.
The drug’s prescribing information warns of suicidal thoughts and behaviors, eye lens clouding in pediatric patients and possible harm to a developing fetus.
- Who
- Sanofi makes Infilbray for adults and children with type 3 Gaucher disease who weigh at least 15 kilograms.
- What
- The FDA approved the pill as the first treatment for the disease’s neurologic symptoms.
- When
- Wednesday, November 18, 2026, according to the article’s publication date and reference to Wednesday.
- Where
- The United States.
- Why
- The drug is designed to stop the buildup of glycosphingolipids and slow disease progression.
This story does not have two clearly opposing sides.
Sanofi acquired Genzyme and took ownership of Infilbray.
The FDA approved Infilbray for neurologic symptoms of type 3 Gaucher disease.
- Drug
- Infilbray (venglustat) tablets
- Manufacturer
- Sanofi
- Eligible patients
- Adults and children weighing at least 15 kilograms
- Trial result
- A year of treatment was associated with statistically significant neurological symptom improvements
- Approval
- First treatment approved for neurologic symptoms of type 3 Gaucher disease
3 sources
What people are saying
Today’s Infilbray approval marks a long-awaited advancement for those experiencing devastating neurological symptoms of Type 3 Gaucher disease.